These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 8548874)

  • 21. The effect of fatty acids and analogues upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance.
    Abulrob AN; Mason M; Bryce R; Gumbleton M
    J Drug Target; 2000; 8(4):247-56. PubMed ID: 11144235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells.
    Tidefelt U; Prenkert M; Paul C
    Cancer Chemother Pharmacol; 1996; 38(5):476-80. PubMed ID: 8765443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.
    Baldini N; Scotlandi K; Serra M; Shikita T; Zini N; Ognibene A; Santi S; Ferracini R; Maraldi NM
    Eur J Cell Biol; 1995 Nov; 68(3):226-39. PubMed ID: 8603675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relation between MDR1 mRNA levels, resistance factor, and the efficiency of P-glycoprotein-mediated efflux of pirarubicin in multidrug-resistant K562 sublines.
    Meesungnoen J; Jay-Gerin JP; Mankhetkorn S
    Can J Physiol Pharmacol; 2002 Nov; 80(11):1054-63. PubMed ID: 12489924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transport mechanism of anthracycline derivatives in rat polymorphonuclear leukocytes: uptake of pirarubicin, daunorubicin and doxorubicin.
    Nagasawa K; Nomiyama M; Ohnishi N; Yokoyama T; Iwakawa S; Okumura K
    Biol Pharm Bull; 1994 Sep; 17(9):1305-8. PubMed ID: 7841960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationships between the in vitro cytotoxicity and transport characteristics of pirarubicin and doxorubicin in M5076 ovarian sarcoma cells, and comparison with those in Ehrlich ascites carcinoma cells.
    Nagai K; Nagasawa K; Sadzuka Y; Tsujimoto M; Takara K; Ohnishi N; Yokoyama T; Fujimoto S
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):244-50. PubMed ID: 11935217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of adriamycin cytotoxicity and transport in drug-sensitive and multidrug-resistant Chinese hamster ovary cells by hyperthermia and cyclosporin A.
    Larrivée B; Averill DA
    Cancer Chemother Pharmacol; 2000; 45(3):219-30. PubMed ID: 10663640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting biliverdin reductase overcomes multidrug resistance in leukemia HL60 cells.
    Kim SS; Seong S; Lim SH; Kim SY
    Anticancer Res; 2013 Nov; 33(11):4913-9. PubMed ID: 24222129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Technetium-99m-tetrofosmin would be a substrate for multidrug resistance-associated protein (MRP): comparison between a leukemia cell line with high MRP gene expression and its parental cell line.
    Li XF; Kinuya S; Yokoyama K; Konishi S; Ma YY; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
    Cancer Biother Radiopharm; 2001 Feb; 16(1):17-23. PubMed ID: 11279794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF.
    Frankel AE; Hall PD; McLain C; Safa AR; Tagge EP; Kreitman RJ
    Bioconjug Chem; 1998; 9(4):490-6. PubMed ID: 9667951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transport mechanism of anthracycline derivatives in rat polymorphonuclear leukocytes: uptake and efflux of pirarubicin.
    Nagasawa K; Nomiyama M; Ohnishi N; Yokoyama T; Iwakawa S; Okumura K
    Biol Pharm Bull; 1994 May; 17(5):696-700. PubMed ID: 7920436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
    Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
    Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Difloxacin reverses multidrug resistance in HL-60/AR cells that overexpress the multidrug resistance-related protein (MRP) gene.
    Gollapudi S; Thadepalli F; Kim CH; Gupta S
    Oncol Res; 1995; 7(5):213-25. PubMed ID: 8534927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
    Marbeuf-Gueye C; Broxterman HJ; Dubru F; Priebe W; Garnier-Suillerot A
    Mol Pharmacol; 1998 Jan; 53(1):141-7. PubMed ID: 9443942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased P-glycoprotein expression in multidrug-sensitive and -resistant human myeloma cells induced by the cytokine leukoregulin.
    Evans CH; Baker PD
    Cancer Res; 1992 Nov; 52(21):5893-9. PubMed ID: 1356622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells.
    Takemura H; Urasaki Y; Yoshida A; Fukushima T; Ueda T
    Cancer Res; 2001 Jan; 61(1):172-7. PubMed ID: 11196156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new anthracycline with potent anti-leukemic activity overcomes P-glycoprotein multidrug resistance.
    Andrivon W; Monneret C; Nafziger J; Florent JC; Guillosson JJ
    Leuk Res; 1998 Aug; 22(8):719-25. PubMed ID: 9680099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anthraquinone antitumour agents, doxorubicin, pirarubicin and benzoperimidine BP1, trigger caspase-3/caspase-8-dependent apoptosis of leukaemia sensitive HL60 and resistant HL60/VINC and HL60/DOX cells.
    Nowak R; Tarasiuk J
    Anticancer Drugs; 2012 Apr; 23(4):380-92. PubMed ID: 22198116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance.
    Baran Y; Gür B; Kaya P; Ural AU; Avcu F; Gündüz U
    Hematology; 2007 Dec; 12(6):511-7. PubMed ID: 17852453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.